Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct-Dec;61(4):1221-1226.
doi: 10.47162/RJME.61.4.23.

The immunoexpression of MMP-1 and MMP-13 in eyelid basal cell carcinoma

Irina Maria Mercuţ  1 , Cristiana Eugenia Simionescu, Alex Emilian Stepan, Bianca Cătălina Andreiana, Ana Maria Ciurea, Răzvan Mercuţ, Marius Eugen Ciurea
Affiliations
Free PMC article

The immunoexpression of MMP-1 and MMP-13 in eyelid basal cell carcinoma

Irina Maria Mercuţ et al. Rom J Morphol Embryol. 2020 Oct-Dec.
Free PMC article

Abstract

Basal cell carcinoma (BCC) is the most frequent human malignancy and at the same time the most frequent periocular malignancy, representing almost 80% of all non-melanoma skin cancers and 90% of eyelid cancers. The study included 50 cases of eyelid BCC, out of which 41 were nodular BCC (NBCC) and nine were infiltrative BCC (IBCC), with various Breslow scores (BS) and primary tumor (pT) category. We analyzed the immunoexpression of matrix metalloproteinases (MMPs) 1 and 13 in the tumoral epithelial component (TEC) and inflammatory stromal component (ISC) of BCC in relation to the two histopathological parameters. The immunoreaction for MMP-1 was identified in 41 (82%) cases and for MMP-13 in 46 (92%) cases both in the TEC and ISC of both types of BCC. The statistical analysis revealed that both collagenases had positive/high scores significantly associated with advanced BS. For MMP-1, there were statistical associations in TEC related to IBCC and high pT category, while MMP-13 only revealed statistical association in ISC with high pT. The presence of collagenase MMP-1 and MMP-13 expression in a high number of cases, both in TEC and ISC, confirms their intervention in the tumor progression and proposes these MMPs as potential targets in antineoplastic therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interests.

Figures

Figure 1
Figure 1
(A) NBCC, BS IV; (B) IBCC, BS IV; (C) NBCC, BS III; (D) IBCC, BS III. Anti-MMP-1 antibody immunostaining: (A and B) ×200. Anti-MMP-13 antibody immunostaining: (C and D) ×200. BS: Breslow score; IBCC: Infiltrative basal cell carcinoma; MMP: Matrix metalloproteinase; NBCC: Nodular basal cell carcinoma
Figure 2
Figure 2
(A) Distribution of cases depending on CS TEC MMP-1 and tumor type; (B) Distribution of cases depending on CS TEC MMP-1 and pT category; (C) Distribution of cases depending on CS TEC MMP-1 and BS; (D) Distribution of cases depending on CS ISC MMP-1 and tumor type; (E) Distribution of cases depending on CS ISC MMP-1 and pT category; (F) Distribution of cases depending on CS ISC MMP-1 and BS. BS: Breslow score; CS: Composite score; ISC: Inflammatory stromal component; MMP-1: Matrix metalloproteinase-1; pT: Primary tumor; TEC: Tumoral epithelial component
Figure 3
Figure 3
(A) Distribution of cases depending on CS TEC MMP-13 and tumor type; (B) Distribution of cases depending on CS TEC MMP-13 and pT category; (C) Distribution of cases depending on CS TEC MMP-13 and BS; (D) Distribution of cases depending on CS ISC MMP-13 and tumor type; (E) Distribution of cases depending on CS ISC MMP-13 and pT category; (F) Distribution of cases depending on CS ISC MMP-13 and BS. BS: Breslow score; CS: Composite score; ISC: Inflammatory stromal component; MMP-13: Matrix metalloproteinase-13; pT: Primary tumor; TEC: Tumoral epithelial component
Figure 4
Figure 4
(A) Distribution of CS for MMP-1 and MMP-13 in TEC; (B) Distribution of CS for MMP-1 and MMP-13 in ISC. CS: Composite score; ISC: Inflammatory stromal component; MMP: Matrix metalloproteinase; TEC: Tumoral epithelial component
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rossato LA, Carneiro RC, de Macedo EMS, de Lima PP, Miyazaki AA, Matayoshi S. Diagnosis of aggressive subtypes of eyelid basal cell carcinoma by 2-mm punch biopsy: prospective and comparative study. Rev Col Bras Cir. 2016;43(4):262–269. - PubMed
    1. Deprez M, Uffer S. Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature. Am J Dermatopathol. 2009;31(3):256–262. - PubMed
    1. Allali J, D’Hermies F, Renard G. Basal cell carcinomas of the eyelids. Ophthalmologica. 2005;219(2):57–71. - PubMed
    1. Lacour JP. Carcinogenesis of basal cell carcinomas: genetics and molecular mechanisms. Br J Dermatol. 2002;146(Suppl 61):17–19. - PubMed
    1. Mantese SAO, Berbert ALCV, Gomides MDA, Rocha A. Basal cell carcinoma - analysis of 300 cases observed in Uberlândia - MG, Brazil. An Bras Dermatol. 2006;81(2):136–142.

Substances